Hypertensive patients with well-controlled hypertension after azelnidipine treatment constituted 32.2 % of the entire study population. Of the patients with poorly controlled or masked hypertension selleck chemicals before azelnidipine treatment,

41.0 % and 47.1 %, respectively, achieved morning home SBP of <135 mmHg.   3 After azelnidipine treatment, pulse rates were significantly lowered by week 4, and the effects persisted up to week 16. The mean changes from baseline were −3.5 ± 9.5 beats/min (clinic), −3.7 ± 8.0 beats/min (morning home), and −3.5 ± 7.3 beats/min (evening home), and these significant reductions persisted throughout the period of observation.   4 The incidence of adverse drug reactions was low at 2.92 %, with reactions occurring in 154/5,265 patients.   On the basis of these results, the find more authors consider azelnidipine to be one of the most useful antihypertensive drugs because of its reliable and persistent BP-lowering Saracatinib effects, in addition to its pulse rate-lowering effect. Acknowledgments The authors would like to thank all of the investigators who cooperated with the At-HOME Study and provided valuable data. The authors would also like to thank Rod McNab and Nila Bhana from inScience Communications, Springer Healthcare (Auckland, New Zealand), who provided English-language editing. This assistance, as well as the translation from Japanese to English, was funded by Daiichi Sankyo

Co., Ltd (Tokyo, Venetoclax solubility dmso Japan). Kazuyuki Shimada is now employed by Oyama Municipal Hospital (Tochigi, Japan). Masahiro Komiya is now employed by Daiichi Sankyo Healthcare Co.,

Ltd (Tokyo, Japan). The authors have no other conflicts of interest that are directly relevant to the content of this article. A version of this manuscript was previously published in Japanese in the Journal of Clinical Therapeutics & Medicine [2008;24(12):1083–98]. The publisher of the Journal of Clinical Therapeutics & Medicine has given permission for publication of this article in English. Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. Electronic supplementary material Below is the link to the electronic supplementary material. Supplementary material 1 (PDF 265 kb) References 1. Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation. 2003;107(10):1401–6.PubMedCrossRef 2. Kario K, Eguchi K, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertension. Circulation. 2003;108(10):72e–3e.CrossRef 3. Pickering TG, Davidson K, Gerin W, et al. Masked hypertension. Hypertension. 2002;40(6):795–6.PubMedCrossRef 4. Okubo T, Imai Y, Tsuji I, et al.